We utilize highly promiscuous biotinylation enzymes to capture transient or low-affinity co-repressors, overcoming the major limitation of conventional pull-down methods and uncovering genuinely novel research targets.
Creative Biolabs constitutes a definitive methodological approach for the resolution of complexity inherent in methylation-mediated gene silencing mechanisms. We deliver an unparalleled, unbiased identification of the entire protein complex recruited by Methyl-CpG-Binding Domain (MBD) proteins, such as MeCP2. Consequently, clients are positioned to obtain novel, high-confidence protein targets and the requisite mechanistic data necessary for distinguishing between normal and pathologically altered regulatory states, thereby significantly accelerating the initial phases of specific research compound development.
DNA methylation at CpG dinucleotides is a fundamental mechanism of transcriptional silencing, primarily mediated by MBD proteins, such as MeCP2. This methodology addresses the challenge presented by the methylation mark's complexity, which arises from up to fifteen chemical combinations due to TET enzyme activity. The service yields an unbiased, high-resolution inventory of the corepressor complexes recruited by these MBD proteins, thereby advancing epigenetic profiling toward definitive mechanistic discovery.
For an in-depth analysis of how our services can be tailored to your specific project needs, request a consultation.
Fig.1 MeCP2 structure and function in gene regulation and chromatin remodeling. 1
We utilize highly promiscuous biotinylation enzymes to capture transient or low-affinity co-repressors, overcoming the major limitation of conventional pull-down methods and uncovering genuinely novel research targets.
Our protocols are optimized to address the challenge of differential binding across the fifteen possible combinations of modified CpGs, ensuring accurate read-out of the full regulatory landscape.
We provide full support for custom cell model engineering, including the development of stable or inducible cell lines with MBD gene tagging in client-provided or commercial cell backgrounds.
We offer optional service extensions to validate protein occupancy at multiple, specific genomic loci of interest (e.g., specific promoter regions, enhancer elements), confirming locus-specific complex composition.
The service represents a sophisticated convergence of distinct technologies, transcending mere incremental changes to established protocols. This novel integration is specifically engineered to address and surpass inherent deficiencies observed in traditional epigenetic analytical methods.
By design, the platform rigorously addresses the historical constraints of classic epigenetic analysis, which often fails to capture transient or complex molecular interactions. This systematic approach ensures the comprehensive discovery of relevant biological mechanisms.
A foundational commitment to producing data of exceptionally high fidelity and resolution underpins the entire service delivery. This precise molecular mapping is essential for establishing robust and statistically reliable findings in complex biological systems.
The provision of highly validated, granular mechanistic data empowers critical, high-stakes research and development decision-making processes. This level of confidence is indispensable for the precise prioritization of early-stage therapeutic research candidates.
To fully understand the Creative Biolabs advantage, we invite you to get a quote today.
Yes. Research shows that MeCP2 mutants exhibit altered binding profiles for specific modified CpG combinations. Our PL-MS approach is sensitive enough to detect how these mutations change the pattern of recruited co-repressors, providing molecular targets for research to selectively inhibit the altered function of the mutant protein.
We accept a wide range of samples, including primary cell cultures and established cell lines (with stable or inducible tagging options). We can optimize for low cell counts typical of complex biological models. The main requirement is high-quality input DNA and/or a viable cell model for genetic tagging.
Provides the gold standard, single-base resolution map of your entire methylome. Use this to identify the initial set of differentially methylated regions (DMRs) that your MBD complex mapping service will then investigate mechanistically.
Learn More →We utilize sophisticated animal models and primary patient-derived xenografts to rigorously assess the in vivo efficacy, pharmacokinetics, and safety of novel small molecules targeting MBD-complex components identified by our service.
Learn More →Creative Biolabs delivers the definitive molecular blueprint of gene silencing, thereby facilitating the transition of research from correlative observation to mechanistic causation. This capability, underpinned by two decades of epigenetic specialization, is instrumental in accelerating the therapeutic research pipeline. The engagement of our expert team is invited for further inquiries and detailed project consultation. Please contact us.
Reference